Global Information
회사소개 | 문의 | 비교리스트

결합 백신 시장 : 규모, 점유율, 전망, 기회 분석

Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

리서치사 Coherent Market Insights
발행일 2019년 06월 상품 코드 883790
페이지 정보 영문
가격
US $ 4,500 ₩ 5,293,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,234,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,763,000 PPT Turned PDF (Enterprise User License)


결합 백신 시장 : 규모, 점유율, 전망, 기회 분석 Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
발행일 : 2019년 06월 페이지 정보 : 영문

세계의 결합 백신(Conjugate Vaccine) 시장에 대해 조사했으며, 시장 성장 촉진요인 및 저해요인, 규제 및 동향, 제품 유형·질병의 적응증·병원체 유형·환자 유형·지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리했습니다.

목차

제1장 조사 목적 및 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 개요

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약
    • 제품 유형별
    • 질병 적응증별
    • 병원체 유형별
    • 환자 유형별
    • 지역별
  • COM(Coherent Opportunity Map)

제3장 시장 역학, 규제 및 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 영향 분석
  • 시장 동향
  • 주요 개발
  • 제품 파이프라인 분석
  • 투자와 정부 이니셔티브
  • GAVI 및 PATH 프로그램 상세
  • 인수합병
  • 규제 시나리오
  • Porter's Five Forces 분석
  • PEST 분석

제4장 세계의 결합 백신 시장 : 제품 유형별

  • 서론
  • 단가 결합 백신
  • 다가 결합 백신

제5장 세계의 결합 백신 시장 : 질병 적응증별

  • 서론
  • 폐렴구균
  • 인플루엔자
  • 수막염균
  • 장티푸스

제6장 세계의 결합 백신 시장 : 병원체 유형별

  • 서론
  • 박테리아
  • 바이러스

제7장 세계의 결합 백신 시장 : 환자 유형별

  • 서론
  • 소아
  • 성인

제8장 세계의 결합 백신 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동
  • 아프리카

제9장 경쟁 구도

  • 히트 맵 분석
  • 기업 개요
    • Sanofi S.A.
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Bharat Biotech
    • Serum institute of India Pvt. Ltd
    • Biological E. Limited.
    • Bio-Med
  • 애널리스트의 의견

제10장 섹션

  • 참고 문헌
  • 조사 방법
  • 당사와 판매에 대해
LSH 19.07.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.

Market Dynamics:

Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2017, 11.9 - 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.

Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.

This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.

Key features of the study:

  • This report provides in-depth analysis of the global conjugate vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2018-2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global conjugate vaccine market based on the following parameters - company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global conjugate vaccine market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Conjugate vaccine market, By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
  • Global Conjugate vaccine market, By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
  • Global Conjugate vaccine market, By Pathogen Type:
    • Bacterial
    • Viral
  • Global Conjugate vaccine market, By Patients Type:
    • Pediatric
    • Adults
  • Global Conjugate vaccine market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type:
    • Pediatric
    • Adults
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type:
    • Pediatric
    • Adults
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
  • Company Profiles
    • Sanofi S.A *
      • Company Overview
      • Technology Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech.
    • Serum institute of India Pvt. Ltd.
    • Biological E. Limited
    • Bio-Med

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Disease Indication
    • Market Snippet, By Pathogen Type
    • Market Snippet, By Patient Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Pipeline Analysis
  • Investments and Government Initiatives
  • GAVI and PATH Program Details
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Conjugate Vaccine Market, By Product Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Monovalent Conjugate Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Multivalent Conjugate Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Conjugate Vaccine Market, By Disease Indication, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Pneumococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Meningococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Typhoid
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Conjugate Vaccine Market, By Pathogen Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Bacterial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Viral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Conjugate Vaccine Market, By Patient Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

8. Global Conjugate Vaccine Market, By Regions, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2016 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2026, (US$ Million)
    • Northern Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Sanofi S.A.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bharat Biotech
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Serum institute of India Pvt. Ltd
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biological E. Limited.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bio-Med
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q